Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil...
Brief Summary
Official Title: “Non-interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or add-on Therapy.”
The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.
- Study Type: Observational
- Study Design: Observational Model: Case-Only, Time Perspective: Prospective
- Study Primary Completion Date: February 2008
Intervention(s) in this Clinical Trial
- Drug: Candesartan Cilexeotil 16mg
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- diagnosis of essential hypertension (mild or moderate as defined in European
- Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o.d. within last 2 weeks or more, according to Romanian approved
- Atacand SPC. Written informed consent to allow access and use(analysis) of data collected
Exclusion Criteria:
- Patients not to be included in the programme: patients who have any contraindication to the product as detailed in Romanian approved Atacand SPC. Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: AstraZeneca Industry
Overall Clinical Trial Officials and Contacts
Mihai Isvoranu Study Chair AstraZeneca
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00573742
Study ID Number: NIS-CRO-ATA-2007/1
ClinicalTrials.gov Identifier: NCT00573742
Health Authority: Romainia: National Drug Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00573742
